GLP-1 therapies represent a landmark breakthrough in treating obesity as the chronic disease it truly is, offering millions a chance to overcome a condition that kills 3.7 million people annually and costs the global economy $3 trillion by 2030. These medications deliver up to 20% weight loss and slash heart attack, stroke and death risks by 20% after three years, providing the first genuinely effective treatment option for a billion people suffering worldwide. The WHO's addition of these drugs to essential medicine lists confirms their critical role in comprehensive care that combines medication with nutrition and exercise support.